翰宇药业（300199）6月30日晚间发布2025年半年度业绩预告显示，公司业绩延续了一季度强劲增长态 势。期内，该公司预计实现归属净利润1.42亿元至1.62亿元，较去年同期大幅增长1470.82%至 1663.89%。 目前，翰宇药业国际化业务已遍布全球核心市场，原料药销往20余个国家和地区，制剂通过对外授权签 约90余个国家和地区。 在创新药研发领域，翰宇药业以"多肽+小核酸"为技术核心，始终聚焦前沿，成果丰硕。公司开发的 HY3003项目，作为一款利用"硅基多肽芯片+AI算法技术"筛选的GLP-1R/GIPR/GCGR三靶点受体激动 剂，目前已完成临床前候选化合物筛选，推进原料药中试放大阶段。该项目采用多剂型并行的开发策 略，开发方向包括周制剂、超长效月制剂、口服制剂。其中，每月注射一次的超长效制剂依托公司自主 长效递送平台，降低给药频率，平稳血药浓度，以期减少胃肠道不良反应，从而提高用药依从性。 翰宇药业表示，除HY3003外，公司在多肽和小核酸制剂的未来管线储备丰富，接下来会陆续面向全球 市场推出不少于20种的制剂，包括原创新药、微创新药、ANDA等，丰富的管线储备为公司持续发展注 入强劲动力。包 ...

Core Insights - Hanyu Pharmaceutical (300199) has recently conducted investor research, discussing the progress of the HY3003 new drug project, its layout in the innovative drug field, and overseas market expansion [1][2] Group 1: HY3003 New Drug Project - The HY3003 project has completed preclinical candidate compound screening and raw material process development, officially entering the raw material pilot scale-up phase, which validates the producibility of the molecular structure for subsequent IND application and clinical transformation [1] - HY3003 is a GLP-1R/GIPR/GCGR receptor agonist developed using AI peptide chip technology, aimed at weight loss indications [1] - The project employs a multi-formulation parallel development strategy, including weekly, ultra-long-acting monthly, and oral formulations, with the ultra-long-acting formulation designed to reduce dosing frequency and improve medication adherence [1] Group 2: siRNA and Other Drug Developments - The company is also developing siRNA drugs such as Inclisiran and Zilebesiran for treating high cholesterol and hypertension, as well as Pegcetacoplan for treating geographic atrophy [1] Group 3: Overseas Market Expansion - Currently, the company's raw materials are sold to over 20 countries and regions, with formulations licensed in over 90 countries and regions [2] - The company has signed cooperation agreements for the semaglutide injection (weekly formulation) and oral tablets in markets including China, Brazil, Egypt, Mexico, Eurasian Union, GCC member countries, and North Africa [2] - The company has completed the enrollment of all participants in the Phase III clinical trial for semaglutide injection as of January this year, with plans to submit for approval in China by 2026, followed by the US and other global markets [2] Group 4: Future Pipeline - Hanyu Pharmaceutical has a rich pipeline of peptide and small nucleic acid formulations, planning to launch no less than 20 formulations over the next 10 years, including innovative drugs, micro-innovative drugs, and ANDA [2]